Cogent Biosciences, Inc.
Clinical trials sponsored by Cogent Biosciences, Inc., explained in plain language.
A clinical-stage biotech company developing precision therapies for genetically defined diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets gene flaws in hard-to-treat bile duct cancer Results expected Mar 2027 (estimated)
-
New hope for rare blood cancer: experimental drug targets mast cells
Disease control Recruiting nowThis study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo offered to GIST patients with no other options
Disease control Expanded accessThis expanded access program provides bezuclastinib, an investigational drug, combined with sunitinib for adults with advanced gastrointestinal stromal tumors (GIST) who cannot tolerate or have progressed on imatinib. The goal is to offer a potential treatment when no satisfactor…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control Expanded accessThis program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo therapy aims to slow advanced GIST
Disease control Recruiting nowThis study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib helps people with advanced GIST live longer without their cancer growing. About 482 adults with GIST that cannot be removed by surgery or has spread will take part. The goal is to see if …
Phase 3 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC